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Abstract
Background: Virus neutralization test (VNT) is widely used for serological survey of classical swine fever (CSF) and
efficacy evaluation of CSF vaccines. However, VNT is a time consuming procedure that requires cell culture and live
virus manipulation. C-strain CSF vaccine is the most frequently used vaccine for CSF control and prevention. In this
study, we presented a neutralizing monoclonal antibody (mAb) based competitive enzyme-linked immunosorbent
assay (cELISA) with the emphasis on the replacement of VNT for C-strain post–vaccination monitoring.
Results: One monoclonal antibody (6B211) which has potent neutralizing activity against C-strain was generated. A novel
cELISA was established and optimized based on the strategy that 6B211 can compete with C-strain induced neutralizing
antibodies in pig serum to bind capture antigen C-strain E2. By testing C-strain VNT negative pig sera (n= 445) and C-strain
VNT positive pig sera (n= 70), the 6B211 based cELISA showed 100% sensitivity (95% confidence interval: 94.87 to 100%) and
100% specificity (95% confidence interval: 100 to 100%). The C-strain antibody can be tested in pigs as early as 7 days post
vaccination with the cELISA. By testing pig sera (n= 139) in parallel, the cELISA showed excellent agreement (Kappa = 0.957)
with VNT. The inhibition rate of serum samples in the cELISA is highly correlated with their titers in VNT (r2 = 0.903, p< 0.001).
In addition, intra- and inter-assays of the cELISA exhibited acceptable repeatability with low coefficient of variations (CVs).
Conclusions: This novel cELISA demonstrated excellent agreement and high level correlation with VNT. It is a reliable tool
for sero-monitoring of C-strain vaccination campaign because it is a rapid, simple, safe and cost effective assay that can be
used to monitor vaccination-induced immune response at the population level.
Keywords: Classical swine fever (CSF), C-strain, Monoclonal antibody, Competitive ELISA (cELISA), Virus neutralization test
Background
Classical swine fever (CSF) is a highly contagious viral dis-
ease of swine, including wild (feral) and domestic pigs [1].
In many regions of the world, CSF is still endemic and is
regarded as one of the major problems in pig industry [2].
CSF has the potential to cause devastating epidemics, par-
ticularly in countries free of the disease such as the United
States [3, 4]. CSF control is primarily dependent on
vaccination and the conventional Chinese vaccine (C-
strain) is considered as one of the most effective vaccines
because of its safety, quick protective immune response,
crosss-protection against challenge of CSF viruses from dif-
ferent genotypes, and ability to be used for oral
immunization of wild boars [2, 5–9].
The etiologic agent of CSF, classical swine fever virus
(CSFV), is one member of the genus Pestivirus of the
Flaviviridae family [10]. CSFV genome is comprised of a
single large open reading frame (ORF) coding for a poly-
protein encompassing all the viral proteins: four struc-
tural (C, Erns, E1, and E2) and eight nonstructural viral
proteins (Npro, p7, NS2, NS3, NS4A, NS4B, NS5A, and
NS5B) [11, 12]. The envelope glycoprotein E2 is respon-
sible for eliciting neutralizing antibodies which are
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protective against virulent CSF virus and is also the tar-
get antigen for development of CSF vaccines, molecular
and serological tests [13–16]. High sequence variability
has been found in E2 protein among CSFVs. Based on the
full-length E2 gene sequences, CSFV isolates could be di-
vided into three genotypes (1, 2, and 3) as well as 11 subge-
notypes (1.1–1.4, 2.1a, 2.1b, 2.1c, 2.1d, 2.2, 2.3, and 3.4) [17].
Virus neutralization test (VNT) is considered as the
gold standard for serological monitoring and efficacy
evaluation of CSF vaccines. However, it has several limi-
tations including time-consuming, requirement of cell
culture, the need for live virus manipulation, and rela-
tively expensive [2, 18–21]. Here, we described a com-
petitive ELISA (cELISA) developed with a neutralizing
anti-E2 monoclonal antibody. This novel cELISA is a
rapid, simple, safe and cost effective approach for detec-
tion of C-strain CSF vaccine-induced immune response.
Results
Generation of suitable capture antigen and competitive
monoclonal antibodies
The envelope glycoprotein E2 of C-strain CSFV was suc-
cessfully expressed in insect cells by using Bac-to-Bac®
Baculovirus Expression System. The purified C-strain E2
protein mainly exists as homodimers (the native dimeric
conformation) under non-reducing condition with a mo-
lecular weight of ~ 90 kDa (Fig. 1a).
To generate suitable mAb for the cELISA, purified C-
strain E2 protein was used as immunogen for mAb pro-
duction using Balb/c mice. All mice maintained good
physical health and no adverse event happened during
the experiments. Spleen cells from one mouse with the
highest anti-E2 antibody titer were collected for fusion.
One panel of more than 5 mAbs against C-strain E2
protein was generated. After assessment by VNT, mAb
6B211 (IgG1 and kappa chain) showed the most potent
neutralizing activity against C-strain CSFV. 6B211 only
react with homodimer of E2 protein and cannot
recognize the reduced proteins, which indicate that it
recognize the conformational epitope of C-strain E2 pro-
tein (Fig. 1b). The neutralization titer (neutralization
doses 50%, ND50) of its purified supernatant (1 mg/ml
with 1920 ND50) is much higher than that of the com-
mercial neutralizing E2 monoclonal antibody WH303 (1
mg/ml with 480 ND50) (Fig. 2a). In addition, 6B211 lacks
cross-reaction with other viruses in genus Pestivirus
such as Bovine viral diarrhea virus (BVDV) (Fig. 2b).
Establishment of competitive ELISA based on C-strain E2
protein and 6B211
Optimal concentrations of capture protein (C-strain
E2) and competitive mAb (horseradish peroxidase
conjugated 6B211, HRP-6B211) were determined by
a systematic checkerboard procedure (Fig. 3a). A
concentration of 0.625 μg/ml of C-strain E2 protein
and a concentration of 1.25 μg/ml of HRP-6B211
were chosen as they consistently produced an
OD450 value around 1.7 and at a point in the linear
range in the standard curve. 2% fetal bovine serum
(FBS) in phosphate buffered saline (PBS) containing
0.05% Tween 20 (PBST) was chosen as the optimal
blocking buffer as it consistently outperformed
other blocking solutions (non-fat dry milk and BSA)
in terms of high signal to noise ratio. To minimize
the volume of serum required and background
Fig. 1 Analysis of purified C-strain E2 protein and monoclonal
antibody 6B211. a Purified C-strain E2 protein mainly exists in its
native dimeric conformation. After purification steps, the purified
insect cell expressed C-strain E2 protein were treated without
(Native) or with β-mercaptoethanol (Reduced) and separated by
SDS-PAGE in a Mini-Protean TGX Gel (Bio-Rad, CA, USA); b 6B211
only react with the native C-strain proteins. Purified E2 proteins
(native or reduced) were loaded on Mini-Protean TGX Gel. The
proteins were then transferred to PVDF membrane and the
membrane were blocked and incubated with 6B211
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noise, serum dilution of 1:5 was chosen as the pre-
ferred dilution over lower dilutions that performed
only slightly better (Fig. 3b). These conditions were
used in all subsequent cELISA experiments.
Reproducibility of the cELISA
The reproducibility of the cELISA was determined by calcu-
lating the coefficient of variation (CV) of the percent of in-
hibition (PI) values by testing 20 C-strain VNT negative pig
serum samples and 20 C-strain VNT positive pig serum
samples. The intra-assay CVs of the C-strain VNT positive
samples ranged from 0.02 to 1.68%. The inter-assay CVs of
those same samples ranged from 1.02 to 8.66%. The intra-
assay and inter-assay of the C-strain VNT negative samples
also exhibited excellent repeatability, showing 0.01–0.35%
and 0.66–4.29%, respectively (Table 1).
Comparison of 6B211 based cELISA with VNT
A total of 139 pig serum samples were tested using the estab-
lished cELISA and VNT in parallel. Results (Table 2) showed
that cELISA and VNT had an excellent agreement (Kappa =
0.957) in identifying positive (from pigs vaccinated with C-
strain vaccine) and negative samples. McNemar’s test revealed
that there was no significant difference in the results between
the cELISA and VNT (P> 0.1). The Pearson correlation coeffi-
cient between the inhibition rate in 6B211 based cELISA and
titers in VNT was calculated (Fig. 4) based on testing results
of the 139 samples. The inhibition rate is highly correlated
with VNT titers for these samples (r2 = 0.903, p< 0.001).
Standardization of the cut-off value of 6B211 based
cELISA
A total of 515 pig serum samples were used to standardize
the cut-off value of the established cELISA. Among them,
445 samples were C-strain VNT negative and 70 samples
were C-strain VNT positive (21 to 56 days post vaccin-
ation, DPV). After testing these samples by the established
cELISA, distributions of the cELISA PI values showing the
frequency of positive and negative samples are calculated
and shown in Fig. 5. The mean PI value (x-axis) of the
negative sera detected by cELISA was − 0.59%. When
mean PI of negative sera plus two standard deviation (SD,
4.03%) was used as threshold, the sensitivity and specificity
of the cELISA were 100% (95% confidence interval: 94.87
to 100%) and 98.43% (95% confidence interval: 96.79 to
99.37%), respectively. When mean PI of negative sera plus
three SD (6.19%) was used as threshold, the sensitivity and
specificity of the cELISA were 100% (95% confidence
interval: 94.87 to 100%) and 100% (95% confidence inter-
val: 100 to 100%), respectively.
Kinetics of antibody response of pigs at different time
intervals post-vaccination
Serial serum samples (0 to 56 DPV at every 7 days) de-
rived from two pigs vaccinated with C-strain were tested
by the established cELISA. The C-strain antibody could
be tested in both pigs as early as 7 DPV with inhibition
values 24 and 56%, respectively. Significant increase of
inhibition was observed between 7 DPV and 28 DPV.
Fig. 2 Neutralizing activity and cross-reaction testing of 6B211. a 6B211 has potent neutralizing activity against C-strain; ST cells were incubated
with CSFV C-strain virus (100 TCID50) and two-fold serial dilutions (1:320 to 1:5120) of mAb 6B211 (1 mg/ml) or WH303 (1 mg/ml); 3 days post
infection (DPI); no green fluorescent signal means 100% inhibition of C-strain virus; b 6B211 lacks cross-reactivity to BVDVs tested by IFA. Cells:
MDBK; inoculated viruses: BVDV-32 (genotype 1, BVD-1), BVDV-0427 (BVD-1), BVDV-AV6 (BVD-1), and BVDV-125 (Genotype 2, BVD-2); 3 DPI; no
green fluorescent signal means without reaction with BVDVs
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The levels of antibody titer kept relatively stable from 28
DPV to 56 DPV with inhibition values ranging from 68
to 86% (Fig. 6).
Discussion
In this study, we developed a neutralizing mAb based
cELISA with the emphasis on the replacement of VNT for
C-strain post–vaccination monitoring. Several monoclonal
antibody-based cELISAs have been developed for detection
and titration of antibodies against different viruses. One
study developed a cELISA based on a mAb to a neutralizing
epitope of hemagglutinin protein of peste des petits rumi-
nants virus (PPRV). Efficacy of the cELISA compared very
well with VNT having high relative specificity (98.4%) and
sensitivity (92.4%). Findings suggest that the cELISA test
developed can easily replace VNT for sero-surveillance,
sero-monitoring, diagnosis from paired sera samples and
end-point titration of PPRV antibodies [22]. Another study
developed a cELISA for detecting antibodies against canine
distemper virus (CDV) and phocine distemper virus (PDV)
in sera from dogs and various species of marine mammals.
Fig. 3 Determination of concentrations of capture antigen &
competitive antibody, and dilution of serum. a Determination of
optimal concentrations of capture protein (C-strain E2) and
competitive antibody (HRP-6B211); the optimal concentration of
capture protein (0.625 μg/ml) and HRP-6B211 (1.25 μg/ml) was
chosen as it consistently produced an OD450 around 1.7 and at a
point in the linear range that allowed optimal inhibition; b
Determination of an optimal dilution of serum; To minimize the
volume of serum required and background noise, serum dilution of
1:5 was chosen as the preferred dilution over lower dilutions that
performed only slightly better. Data are expressed as the mean ±
standard deviation from independently repeated experiments
Table 1 Coefficient values of the samples tested by 6B211
based cELSIA





C-strain VNT positive 20 0.02–1.68 1.02–8.66
C-strain VNT negative 20 0.01–0.35 0.66–4.29
Table 2 Comparison of 6B211 based cELISA with VNT
cELISA VNT
Number positive 66 69
% Positive 47.5% 49.6%
Number negative 73 70
% Negative 52.5% 50.4%
Result agreement (Kappa) 0.957
Significance P > 0.1
Note. Significance: P < 0.05 = tests are significantly different at the 95%
confidence level
Fig. 4 Correlation of inhibition rate of 6B211 based cELISA and titers
of VNT against C-strain. Data represent the mean of independently
repeated experiments
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The authors suggested that as cELISA proved to be nearly
as sensitive and specific as the VNT while being simpler
and more rapid, it would be an adequate screening test for
CDV or PDV cases [23]. The glycoprotein E2 exposed on
the outer surface of CSFV is the major immuno-protective
antigen of C-strain vaccine that is responsible for inducing
neutralizing antibodies and eliciting protective immunity
against CSFV [13–20]. Thus, it is not surprising that E2
protein has been successfully used to develop ELISAs to
measure anti-CSFV antibody response in pigs after vaccin-
ation [13–16]. In this study, the purified insect cell
expressed C-strain envelope glycoprotein E2 was used as
the capture antigen. The insect cell expressed E2 provides
proper refolding, post-translational modification, and
oligomerization [24], which guaranteed the immunodomi-
nant epitopes of E2 protein exposed in their native state.
The mAb 6B211 showed potent neutralizing activity
against C-strain CSFV and bound to a specific conform-
ational epitope on C-strain E2 protein (Fig. 1b & Fig. 2a).
In addition, it showed very high sensitivity when tested
by IFA (mouse ascites of 6B211 produced a strong posi-
tive fluorescence signal at dilution 1:16,000, data not
shown). To test the hypothesis that neutralizing 6B211
can compete with C-strain induced neutralizing anti-
bodies in pig serum to bind the capture antigen (C-
strain E2), 445 C-strain VNT negative pig serum sam-
ples and 70 C-strain VNT positive pig serum samples
were tested by the 6B211 based cELISA. The 6B211
based cELISA can effectively differentiate the C-strain
VNT positive and C-strain VNT negative samples
(Fig. 5), which indicate that 6B211 can compete with C-
strain induced neutralizing antibodies from pigs and can
be used as the competitive antibody for cELISA.
By testing the pig sera in parallel and using mean PI of
negative sera plus three SD as the threshold, the sensitiv-
ity and specificity of the cELISA were 100% (95% confi-
dence interval: 94.87 to 100%) and 100% (95%
confidence interval: 100 to 100%), respectively. The C-
strain antibody can be tested in pigs as early as 7 DPV
with the cELISA. The excellent agreement (Kappa =
Fig. 5 Standardization of the cut-off value of 6B211 based cELISA. a C-strain VNT negative serum samples (n = 445); b C-strain VNT positive serum
samples (n = 70). The dotted line represents cut-off value of 6.19% inhibition when using the mean PI of negative sera plus three SD as
the threshold
Fig. 6 Kinetics of antibody responses of pigs tested by 6B211 based
cELISA. Serum samples were derived from C-strain vaccinated pigs
(n = 2) at every 7 days. The dotted line represents cut-off value: 19
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0.957, Table 2) between cELISA and VNT, and the high
correlation VNT (r2 = 0.903) between inhibition rate in
cELISA and VNT titers of tested samples indicate that
the 6B211 based cELISA can replace the VNT for C-
strain post–vaccination monitoring. In addition, the
intra-assay CVs and the inter-assay CVs of the 6B211
based cELISA (Table 2) are lower than 10% when tested
with the negative and E2 antibody positive pig serum
samples, which indicate that the established cELISA is
repeatable with acceptable variations.
Conclusions
Through the aforementioned experiments and analysis, we
concluded that the mAb 6B211 based cELISA showed excel-
lent agreement and high correlation with the VNT. This
cELISA is a reliable, rapid, simple, safe, and cost-effective tool
for sero-monitoring of C-strain vaccination at a population
level. We believe that the cELISA presented in this study
could be used to assist in CSF control and eradication.
Methods
Animals
Five female Balb/c mice (6 weeks old) weighing between
22 and 25 g were purchased from Charles River Labora-
tories, Inc. Wilmington, MA, USA. The mice were fed
with standard commercial diet and housed in a clean fa-
cility at the Kansas State University. Animal care and
protocols were approved by Institutional Animal Care
and Use Committee (IACUC#3517) at Kansas State Uni-
versity. All animal experiments were done under strict
adherence to the IACUC protocols.
Generation of monoclonal antibody to C-strain E2 protein
Expression and purification of C-strain E2 protein using
a baculovirus expression system were performed as pre-
viously described [18]. The purified C-strain E2 protein
was concentrated using Amicon Ultra Centrifugal Filters
30,000 NMWL (Millipore, Billerica, USA) and measured
using BCA assay kit (Pierce, USA) according to the man-
ufacture’s recommendations.
For mAb production, 50μl (1μg/μl) purified E2 protein plus
equal volume of 2% Alhydrogel (Invitrogen, CA, USA) was
used as an immunogen to inject each of the Balb/c mice via
intraperitoneal injection. Three booster immunizations with
same dose were conducted at 2week intervals. Three days
after the final booster injection, one mouse with the highest
anti-E2 antibody titer was humanely euthanized using carbon
dioxide (CO2) in euthanasia chambers and sprayed with 70%
ethanol. Spleen cells were collected and fused with the mouse
myeloma partner SP2/0-Ag14 (ATCC, MD, USA) by using
polyethylene glycol 1500 (Boehringer Mannheim, IN, USA) at
a ratio of 10:1. The hybridoma cells were maintained in
RPMI1640 medium (Gibco, NY, USA) with 20% fetal bovine
serum (FBS, Hyclone, UT, USA). Supernatants from growing
hybridomas were screened by an ELISA for reactivity to E2
protein as previously described [18]. The positive hybridoma
clones were subcloned three times by limiting dilution until
monoclones were obtained. Characterization of these mono-
clonal antibodies will be published elsewhere. One mAb, des-
ignated 6B211 was used in this study. Its isotype was classified
with an antibody-isotyping kit (Roche Diagnostics Corpor-
ation, IN, USA). The reaction of 6B211 with native and β-
mercaptoethanol treated C-strain E2 protein was analyzed by
western blot as we described previously [18].
Indirect fluorescent antibody assay (IFA) test
The reactivity of mAb with different BVDVs was tested by
IFA as described previously [25]. Briefly, MDBK cells (bo-
vine kidney cells, ATCC, CCL22) grown in 96-well plate
were infected with BVDVs (BVDV-32 strain, genotype 1;
BVDV-0427 strain, genotype 1; BVDV-AV6 strain, geno-
type 1; BVDV-125 strain, genotype 2) at a multiplicity of in-
fection (MOI) of 0.1 for 3 days. Cells were fixed in cold
acetone and washed two times with PBST. Supernatant of
hybridomas (1:50 diluted) was added and plates were incu-
bated at 37 °C for 1 h (hr). Plates were washed three times
with PBST and Alexa Fluor 488 goat anti-mouse IgG (H+
L) (Life Technologies, MA, USA) was added at 1:200 dilu-
tion to each well and incubated at 37 °C for 1 h. Finally, the
plate was washed three times with PBST and examined
under a fluorescence microscope.
Neutralizing antibody test
Purified mAbs 6B211 (1mg/ml) and WH303 (1mg/ml, Ani-
mal and Plant Health Laboratories Agency, Wey Bridge,
United Kingdom) were first diluted five-fold and then serially
diluted two-fold. The diluted samples (in duplicate) were in-
cubated with 100 TCID50 (50% tissue culture infective dose)
of CSFV C-strain in DMEM with 10% FBS for 1 h at 37 °C.
Residual virus infectivity was determined by adding 1.0 × 104
ST cells to each well with serum-virus mixture in 96-well
plate and incubated at 37 °C for 3 days. The cells were sub-
jected to immunofluorescence staining with E2-specific mAb
WH303 and Alexa Fluor 488 goat anti-mouse IgG (H+ L)
(Life Technologies, MA, USA). Neutralizing antibody titers
(NAT) were expressed as the reciprocal of the highest dilu-
tion that caused 50% neutralization.
Competitive enzyme-linked immunosorbent assay
(cELISA)
The 6B211 was purified by HiTrap™ Protein G column
(GE Healthcare Life Sciences, PA, USA) followed by
conjugating with Horseradish Peroxidase (HRP) using
EZ-Link™ Plus Activated Peroxidase (Thermo Scientific,
NJ, USA) according to the manufacturer’s instruction.
The HRP-6B211 was dialyzed with Slide-A-Lyzer Dialy-
sis Cassettes (Thermo Scientific, NJ, USA) against PBS
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and stored in Pierce™ Peroxidase Conjugate Stabilizer
(Thermo Scientific, NJ, USA).
The systematic checkerboard procedure was used to
optimize the concentration of capture antigen and HRP-
6B211. The optimal dilution of serum and blocking solu-
tion were determined experimentally. The established
cELISA was performed in Corning® 96 Well Clear Flat
Bottom Polystyrene High Bind Microplate (Corning, NY,
USA). Briefly, plates were coated overnight with C-strain
E2 (0.625 μg/ml, 100 μl/well) in PBS (without calcium
and magnesium, pH 7.4, Thermo Scientific, NJ, USA) at
4 °C. After washing three times with PBST, the plates
were blocked with blocking buffer by incubating at 37 °C
for 1 h; after washing, 50 μl of diluted serum samples
and 50 μl of diluted HRP-6B211 were added to each well
and mixed well by pipetting. The plates were incubated
at 37 °C for 1 h. After washing five times, 100 μl of
room-temperature TMB Stabilized Chromogen (Invitro-
gen, CA, USA) were added and incubated at room
temperature (RT) for 10 min; after adding 100 μl/well of
2 N Sulfuric Acid (Ricca Chemical Company, TX, USA),
the absorbance at 450 nm were obtained using Spectra-
MAX microplate reader (Molecular Devices, CA, USA).
The OD450 of the samples were converted to a percent
inhibition (PI) value using the following formulation: PI
(%) = (OD450 value of negative controls − OD450 value of
sample)/OD450 value of negative controls × 100%.
The cut-off value that served as the threshold to separ-
ate VNT positive sera from VNT negative sera was de-
termined by testing negative sera of unvaccinated pigs
and VNT positive sera of C-strain or C-strain E2 subunit
vaccinated pigs (21–56 DPV).
Serial derived serum samples after vaccination with C-
strain from 0 to 56 DPV at every 7 days were used for
testing the kinetics of antibody titers of pigs (n = 2) at
different time intervals post-vaccination.
Reproducibility and statistical analysis of the cELISA
Inter-assay and intra-assay reproducibility for the estab-
lished cELISA was evaluated by testing CSFV antibody
negative (n = 20) serum samples and C-strain VNT posi-
tive pig serum samples (n = 20). For the intra-assay re-
producibility, each serum sample (in duplicate) was
detected by the same batch of pre-coated ELISA plates.
For the inter-assay reproducibility, each serum sample
was detected by three batches of pre-coated ELISA
plates. Sensitivity and specificity analysis were carried
out by the web-based MedCalc statistical software
(https://www.medcalc.org/calc/diagnostic_test.php). Stat-
istical analysis of reproducibility was carried out by cal-
culate the mean PI value and coefficient of variation
(CV) of replications of each test. Statistical analysis of
the degree of agreement (Kappa value) and correlation
between the established cELISA and VNT were carried
out by McNemar’s test and Pearson correlation coeffi-
cient analysis in SPSS Statistics for Windows, version
25.0 (IBM Crop, NY, USA). Differences were considered
statistically significant when p < 0.05. Scatter plots was
generated using the same program.
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